# PAXIPEM: HCP commentary report

> 70 verified statements (24 from clinicians verified by NPI or staff page) from 8 commentary sources · 7 findings · updated Oct 31, 2026

## Report

- Trial: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- NCT ID: NCT05096390
- Registry: https://clinicaltrials.gov/study/NCT05096390
- Sponsor: Centre Leon Berard
- Phase: Phase 2
- Status: Unknown
- Drugs tested: axitinib plus pembrolizumab
- Indication: first-line advanced papillary renal cell carcinoma type 2
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: a3e120be915466a97459a70440d00629178c0c5ab2d82d58066448c264efc3eb

## Counts

- HCP commentary sources screened: 24
- Sources cited by verified statements: 9
- Verified statements: 70
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 24
- Findings: 7
- Named people in screened sources (unnamed speakers and accounts not counted): 8
- Voices cited: 8
- Cited voices identity-verified: 6
- Organisational or shared accounts (not counted as people): 1

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

PAXIPEM asks whether adding pembrolizumab to axitinib improves first-line treatment for locally advanced or metastatic type 2 papillary renal cell carcinoma. Commentary comes from X posts, podcasts featuring medical oncologists, and a YouTube roundtable. The discussion turns on how to assess the axitinib rationale amid interest in PAXIPEM and one podcast speaker’s tentative reservation, and whether the papillary RCC trial portfolio can deliver consequential progress while its biological novelty remains debated.

## Open Medical Affairs question

What evidence would demonstrate a clinically meaningful net benefit from adding pembrolizumab to axitinib in this population, and how should that uncertainty be discussed when treatment choice and trial access remain conditional?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. PAXIPEM attracts interest, but its axitinib rationale receives a specific, tentative reservation
- F2. The demand for randomization is about incremental benefit and harm, with a qualified role for homogeneous single-arm studies
- F3. The competing upfront regimen preferences remain conditional and do not establish a standard
- F4. Trial-first preferences have practical exceptions, including a narrowly conditional monotherapy option
- F5. Histology-specific treatment requires diagnostic clarity, but pathology re-review is selective rather than universal
- F6. The portfolio is viewed as potentially consequential, while its biological novelty remains debated
- F7. Existing labels are seen as a barrier, while cooperative groups, partnerships and tissue databanks are valued

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 5 | 6 | 3 | 5 | recorded | 3 |
| F2 | 11 | 13 | 6 | 4 | recorded | 3 |
| F3 | 7 | 7 | 3 | 4 | recorded | 3 |
| F4 | 6 | 6 | 3 | 2 | recorded | 3 |
| F5 | 10 | 11 | 3 | 3 | recorded | 3 |
| F6 | 9 | 7 | 4 | 3 | recorded | 3 |
| F7 | 6 | 5 | 2 | 1 | recorded | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 5 | 0 | 0 | 0 | 0 | 6 | 2 | 2 posts and articles, 1 podcast or video | yes |
| F2 | 7 | 3 | 0 | 0 | 1 | 13 | 1 | 2 posts and articles, 3 podcasts and video, 1 registry | yes |
| F3 | 4 | 2 | 1 | 0 | 0 | 9 | 0 | 1 post or article, 2 podcasts and video | yes |
| F4 | 5 | 0 | 1 | 0 | 0 | 7 | 2 | 3 podcasts and video | yes |
| F5 | 4 | 2 | 2 | 0 | 2 | 13 | 2 | 3 podcasts and video | yes |
| F6 | 8 | 0 | 0 | 1 | 0 | 9 | 0 | 2 posts and articles, 2 podcasts and video | yes |
| F7 | 5 | 1 | 0 | 0 | 0 | 8 | 0 | 2 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.: no finding draws on it directly
- Secondary endpoints: no finding draws on it directly
- Population and setting: F5 (10 shared claims)
- The comparison: F1 (2 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (9 shared claims), F6 (2 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F1. PAXIPEM attracts interest, but its axitinib rationale receives a specific, tentative reservation

A podcast panel addressed the question of disease-specific support for choosing axitinib as the backbone for PAXIPEM’s treatment comparison.

Source: podcast, 2025-03-15.

### F6. The portfolio is viewed as potentially consequential, while its biological novelty remains debated

A YouTube roundtable discussed what clinical and biological questions prospective papillary RCC studies, including PAXIPEM, could address.

Source: YouTube video, 2024-06-17.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 7 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 70 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 9 | Counts free |
| Speaker attribution for cited voices | 8 | Paid |

## Trial aspects

7 discussed · 3 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment. | no commentary found | 0 | 0 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 10 | 3 |
| The comparison | discussed | 2 | 2 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 10 | 5 |
| First-line positioning, alternative regimens and the unresolved standard | discussed | 9 | 3 |
| Trial feasibility, reimbursement, referral and patient support | discussed | 5 | 2 |
| Portfolio expectations, biological development and translational value | discussed | 10 | 3 |
| Rare-disease development incentives, collaborative routes and research collections | discussed | 6 | 2 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 20 | 4 |
| Podcasts | 3 | 3 |
| YouTube | 1 | 1 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2023-02-09 to 2026-10-25
- Cited window: 2023-02-09 to 2025-07-17
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- Registry: NCT05096390 (https://clinicaltrials.gov/study/NCT05096390)
- Study IDs: PAXIPEM (ET21-023) · ET21-023 (Centre Leon Berard)
- Sponsor: Centre Leon Berard
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Unknown
- Enrollment: 72 (estimated)
- Start: 2022-06-01 (actual)
- Primary completion: 2024-10 (estimated)
- Primary endpoint: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment. (At 6 months for each patient)
- Intervention: Axitinib Oral Tablet [Inlyta] (drug)
- Intervention: Pembrolizumab Injection [Keytruda] (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on biomarker-selected checkpoint and targeted combination therapy in advanced papillary kidney cancer, with small-study uncertainty.
- Not yet captured in this edition: a remark on patient-facing trial-finding tools supporting access to papillary kidney cancer research.
- Not yet captured in this edition: a view on uncertainty over appropriate control arms for systemic-treatment trials in advanced papillary renal cell carcinoma.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 128 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed for this edition contain no PAXIPEM outcome data or exact-trial results publication. No separate protocol document or exact product-label documents for either trial drug were available; registry descriptions are planned methods, not observed efficacy or safety.
- Several podcast editions reproduce the same panel, and social posts were reposted. Source totals cannot be interpreted as numbers of independent HCPs, endorsements or a measure of consensus.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Many statements concern metastatic papillary or broader non-clear-cell RCC. Approximate cross-histology figures and preferences for alternative regimens are not type 2 papillary-specific estimates or PAXIPEM comparative findings.
- Regulatory history, reimbursement experience, guideline-access expectations, future practice impact and biological-development forecasts remain the speakers' recollections, interpretations or hopes.
- Publication and post dates do not establish trial readout dates, session timing or changes of mind across settings.
- This report does not detail organization-specific trial-navigation resources or proposals linking molecular and biobank data with institutional treatment experience, including AI-enabled analysis. Its account of participation support and translational strategy is therefore incomplete.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (70 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (6 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/paxipem-nct05096390
- Agents: POST https://www.erudio.com/api/orders with {"report": "paxipem-nct05096390", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=paxipem-05096390

## Cite

Erudio Health. PAXIPEM (NCT05096390): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/paxipem-nct05096390

## Machine access

- JSON: https://www.erudio.com/reports/paxipem-nct05096390.json
- Markdown: https://www.erudio.com/reports/paxipem-nct05096390.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "paxipem-05096390"}`